Unknown

Dataset Information

0

A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challenge.


ABSTRACT: Previous studies have established that strain 68-1-derived rhesus cytomegalovirus (RhCMV) vectors expressing simian immunodeficiency virus (SIV) proteins (RhCMV/SIV) are able to elicit and maintain cellular immune responses that provide protection against mucosal challenge of highly pathogenic SIV in rhesus monkeys (RMs). However, these efficacious RhCMV/SIV vectors were replication and spread competent and therefore have the potential to cause disease in immunocompromised subjects. To develop a safer CMV-based vaccine for clinical use, we attenuated 68-1 RhCMV/SIV vectors by deletion of the Rh110 gene encoding the pp71 tegument protein (?Rh110), allowing for suppression of lytic gene expression. ?Rh110 RhCMV/SIV vectors are highly spread deficient in vivo (~1000-fold compared to the parent vector) yet are still able to superinfect RhCMV+ RMs and generate high-frequency effector-memory-biased T cell responses. Here, we demonstrate that ?Rh110 68-1 RhCMV/SIV-expressing homologous or heterologous SIV antigens are highly efficacious against intravaginal (IVag) SIVmac239 challenge, providing control and progressive clearance of SIV infection in 59% of vaccinated RMs. Moreover, among 12 ?Rh110 RhCMV/SIV-vaccinated RMs that controlled and progressively cleared an initial SIV challenge, 9 were able to stringently control a second SIV challenge ~3 years after last vaccination, demonstrating the durability of this vaccine. Thus, ?Rh110 RhCMV/SIV vectors have a safety and efficacy profile that warrants adaptation and clinical evaluation of corresponding HCMV vectors as a prophylactic HIV/AIDS vaccine.

SUBMITTER: Hansen SG 

PROVIDER: S-EPMC6788755 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications


Previous studies have established that strain 68-1-derived rhesus cytomegalovirus (RhCMV) vectors expressing simian immunodeficiency virus (SIV) proteins (RhCMV/SIV) are able to elicit and maintain cellular immune responses that provide protection against mucosal challenge of highly pathogenic SIV in rhesus monkeys (RMs). However, these efficacious RhCMV/SIV vectors were replication and spread competent and therefore have the potential to cause disease in immunocompromised subjects. To develop a  ...[more]

Similar Datasets

| S-EPMC8284654 | biostudies-literature
| S-EPMC3154277 | biostudies-literature
| S-EPMC4886799 | biostudies-literature
| S-EPMC7441386 | biostudies-literature
| S-EPMC2571929 | biostudies-literature
| S-EPMC8244349 | biostudies-literature
| S-EPMC6789596 | biostudies-literature
2012-08-08 | E-GEOD-40006 | biostudies-arrayexpress
| S-EPMC8354429 | biostudies-literature
| S-EPMC2907403 | biostudies-literature